文献速递心力衰竭与心肌病

维立奴拉联合别嘌醇治疗射血分数保留的心力衰竭:AMETHYST随机临床试验

Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2024-01-01

这项2期双盲随机试验在159例伴高尿酸血症的HFpEF患者中比较维立奴拉联合别嘌醇、别嘌醇单药与安慰剂。联合治疗显著降低血尿酸,但峰值耗氧量和KCCQ症状评分在各组间相似,未观察到显著临床获益。

要点

  • 维立奴拉联合别嘌醇较别嘌醇或安慰剂显著降低血尿酸。
  • 联合治疗未显著改善峰值耗氧量或心力衰竭症状。
  • 各组不良事件无安全信号,联合组死亡或心血管事件数值较低。

核心结论

  • 尽管血尿酸显著降低,维立奴拉联合别嘌醇较别嘌醇单药或安慰剂未显著改善HFpEF患者的峰值耗氧量或症状。

研究设计与样本

  • 2期双盲随机临床试验,2020年5月至2022年4月在12个国家59个中心开展,为期32周。
  • 纳入159例40岁及以上、HFpEF且血尿酸大于6 mg/dL的患者,按1:1:1随机分组,每组53例。

主要发现

  • 维立奴拉联合别嘌醇组血尿酸平均变化-59.6%(95%CI -64.4%至-54.2%),降幅大于别嘌醇组的-37.6%(95%CI -45.3%至-28.9%)和安慰剂组的0.8%(95%CI -11.8%至15.2%),P < .001。
  • 峰值耗氧量变化:联合组0.27 mL/kg/min(95%CI -0.56至1.10),别嘌醇组-0.17 mL/kg/min(95%CI -1.03至0.69),安慰剂组0.37 mL/kg/min(95%CI -0.45至1.19),组间相似。
  • KCCQ-TSS变化:联合组4.3(95%CI 0.3-8.3),别嘌醇组4.5(95%CI 0.3-8.6),安慰剂组1.2(95%CI -3.0至5.3),组间相似。
  • 死亡或心血管事件:联合组3例(5.7%),别嘌醇单药组8例(15.1%),安慰剂组6例(11.3%);未观察到不良安全信号。

临床怎么用

  • 对于HFpEF伴高尿酸血症患者,不推荐仅以降低血尿酸为目的使用维立奴拉联合别嘌醇来改善峰值耗氧量或症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors' knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF. OBJECTIVE: To investigate the efficacy and safety of the novel urate transporter-1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024. INTERVENTIONS: Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization. MAIN OUTCOMES AND MEASURES: Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events). RESULTS: Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro-brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, -59.6%; 95% CI, -64.4% to -54.2%) lowered SUA level to a greater extent than allopurinol (mean change, -37.6%; 95% CI, -45.3% to -28.9%) or placebo (mean change, 0.8%; 95% CI, -11.8% to 15.2%; P < .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, -0.56 to 1.10 mL/kg/min; allopurinol, -0.17 mL/kg/min; 95% CI, -1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, -0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, -3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04327024.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Kitzman, Voors, Mentz, et al. Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 39141378. doi:10.1001/jamacardio.2024.2435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。